In combination with other genes involved in the B-cell development (IKZF1plus signature), the presence of IKZF1 deletions represents a marker currently used for risk stratification in different treatment protocols, including AIEOP-BFM ALL 2017 [62]. This evidence concerns the gene IKZF1 and acute lymphoblastic leukemia.